Laureate Pharma, Inc. - - BioPharm International

ADVERTISEMENT

Laureate Pharma, Inc.

BioPharm International
Volume 19, Issue 12

Company Description



Laureate Pharma, Inc. is a full service contract manufacturing organization (CMO) with headquarters in Princeton, NJ. The company is dedicated to supporting the development and commercialization of pharmaceutical products for pharmaceutical and biopharmaceutical companies. The facility is FDA registered and inspected. The company provides a wide range of product development and manufacturing services from process design and development to full-scale cGMP production, purification and aseptic filling, as well as corresponding testing, validation, analytical services and regulatory support. The primary focus is on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Mammalian cells are grown in stirred-tank bioreactors for production of biopharmaceutical proteins, which are purified by state-of-the-art semiautomated chromatography systems. Modular development programs, as well as complete manufacturing and filling operations, are offered.

Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics (NYSE:SFE).
















Products and Services

  • Process Development
  • Cell Line Development
  • Small-Scale Pilot Reactor Runs
  • Purification Process
  • Bioreactor Production
  • Purification at Scale
  • Protein Modification and Conjugation
  • Aseptic Fill and Finish
















Facilities

  • 57,000 sq.ft. cGMP manufacturing facility
  • Process development laboratories
  • Stirred-tank and hollow-fiber bioreactors (up to 2,500 L)
  • Protein purification skids
  • Two filling lines for clinical-scale aseptic liquid filling










LAUREATE PHARMA INC.
201 College Rd. E. Princeton,
NJ 08540

TELEPHONE
609.919.3400

FAX
609.520.3963

EMAIL

WEB ADDRESS
http://www.laureatepharma.com/

EMPLOYEES
95

FOUNDED
1999

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here